Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
18 Leser
Artikel bewerten:
(0)

Clinical Diagnostics PCR Markets 2017-2021

DUBLIN, July 10, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Clinical Diagnostics PCR Markets by Type (Infectious Disease, Cancer, Cardiovascular, Genetic, Others) and Region (U.S., Europe, Japan, China, Latin America, World) and Technology (PCR, TMA, Other NAAT)" report to their offering.

Research and Markets Logo

This report provides crucial business planning data for companies in the clinical PCR (polymerase chain reaction) and other nucleic acid amplification test (NAAT) markets.

Companies included in this report may be involved research instruments and reagents, platforms and tests for clinical laboratories, and/or platforms and tests for near-patient or point-of-care diagnostics.

Other companies are using PCR technology as the first step of assays that utilize other technologies such as DNA sequencing or mass spectrometry.

PCR is a large field that covers a wide range of activities, and this is reflected in the topics covered in this report.

This Report Includes a Discussion of:





- Overview of PCR and other NAAT technologies


- Applications of NAAT in clinical diagnostic


- Markets by segment (infectious disease, cancer, genetics)


- Sub-segment markets within larger for infectious disease (Hepatitis, HIV, STDs, RSV, Others) and oncology (Screening, Diagnostics) and Genetic (Inherited, Thrombolia, Pharmacogenomics)


- Regional Markets (U.S., Europe, Japan, China, Latin America, World)


- Deals made by PCR and other NAAT companies, including investments and financing agreements, acquisitions, collaborations, and other agreements.


- Market drivers, issues, and trends in the nucleic acid amplification market


- Forecasts projected to 2021


- Profiles of companies reflecting the wide range NAAT products and applications.

Key Topics Covered:





1: Executive Summary



2: Introduction



3: Trends and Innovation



4: Clinical PCR Tests on the Market



5: Polymerase Chain Reaction (PCR) And Nucleic Acid Amplification Test (Naat) Market Analysis



6: Company Profiles



- Abbott Laboratories


- Agilent Technologies Inc.


- Alere Inc.


- Asuragen, Inc.


- Beckman Coulter, Inc. (A Danaher Corporation Company)


- Biocartis Group Nv


- Biofire Diagnostics, Llc. (Acquired By Biomérieux)


- Biomérieux Sa


- Bio-Rad Laboratories, Inc.


- Cepheid (A Danaher Company)


- Genmark Diagnostics, Inc.


- Hologic, Inc.


- Luminex Corporation


- Meridian Bioscience, Inc.


- Qiagen N.V.


- Quantumdx Group


- Quidel, Inc.


- Roche


- Spartan Bioscience Inc.


- Stat-Diagnostica


- T2 Biosystems, Inc.



For more information about this report visit

https://www.researchandmarkets.com/research/xv8pfg/clinical


Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.